Citations

Showing 10 of 108152 citations.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Zakharia, Yousef , Rixe, Olivier , Drabick, Joseph J. , Shaheen, Montaser , Grossmann, Kenneth F. , Kolhe, Ravindra , Pacholczyk, Rafał , Sadek, Ramses , Tennant, Lucinda, Link, Charles J., Vahanian, Nicholas N., Brincks, Erik L. , Rossi, Gabriela R. , Munn, David H. , Milhem, Mohammed , McWilliams, Robert R. , Milhem, Mohammed M , Kolhe, Ravindra , Zakharia, Yousef , Smith, Christopher Matthew , Kennedy, Eugene Paul , Yu, Jiayi , Shen, Steven S.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 11, 2021 | Volume: 9 | Issue: 6 | Pages: e002057

10.1136/jitc-2020-002057 | PMID 34117113 Get It

Background The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity. In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma. Methods Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma. Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I). Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label. Results Between July 2014 and July 2017, 131 patients were enrolled. (P) was used more frequently (n=114, 87%) per investigator’s choice. The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P). The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%. Median progression-free survival was 12.4 months (95% CI 6.4 to 24.9). The ORR for Programmed Death-Ligand 1 (PD-L1)-positive patients was 70% compared with 46% for PD-L1-negative patients. The combination was well tolerated, and side effects were similar to what was expected from single agent (P). Conclusion In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma.
Pharmacogenomic‐Guided Therapy in Colorectal Cancer
Diasio, Robert B. , Innocenti, Federico , Offer, Steven M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 11, 2021 | Volume: 110 | Issue: 3 | Pages: 616-625

10.1002/cpt.2334 | PMID 34114648 Get It

Approximately 20 drugs have been shown to be effective for the treatment of colorectal cancer (CRC). These drugs are from several classes of agents and include cytotoxic drugs, therapeutics that target cell signaling pathways at the extracellular and/or intracellular levels, and combination therapies that contain multiple targeted agents and/or cytotoxic compounds. Targeted therapeutics can include monoclonal antibodies, fusion proteins, and small molecule drugs. The first introduced into clinical use was 5‐fluorouracil in the early 1960s and remains the foundation for most CRC treatments in both adjuvant therapy and in advanced (metastatic) treatment regimens. As with other cancers, the consideration of biomarkers has the potential to improve CRC therapy through patient stratification. The biomarkers can include germline genetic markers, tumor‐specific genetic markers, immune markers, and other biomarkers that can predict antitumor efficacy or the likelihood of toxicity prior to administration of a specific drug. Consistent with the benefit of considering biomarkers in treatment, many newer targeted therapies are developed and approved simultaneously with a companion diagnostic test to determine efficacy. This review will focus on biomarkers that have demonstrated clinical utility in CRC treatment; however, it is noted that many additional biomarkers have been theorized to contribute to drug response and/or toxicity based on known biological pathways but thus far have not attained widespread use in the clinic. The importance of pretreatment biomarker testing is expected to increase as future drug development will likely continue to focus on the concurrent development of companion diagnostics.
Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation
Nelson, Alfred D. , Black, Christopher J. , Houghton, Lesley A. , Lugo‐Fagundo, Nahyr , Lacy, Brian E. , Ford, Alexander C. , Lugo-Fagundo, Nahyr Sofía, Houghton, L A , Ford, Alexander C , Black, Christopher J

Mayo Clinic

Alimentary Pharmacology & Therapeutics | June 11, 2021 | Volume: 54 | Issue: 2 | Pages: 98-108

10.1111/apt.16437 | PMID 34114657 Get It

SummaryBackgroundAlthough bloating is a highly prevalent and troublesome symptom in irritable bowel syndrome with constipation (IBS‐C), treatment is empirical with no specific guidelines for its management.AimTo conduct a pairwise and network meta‐analysis, using a frequentist approach, of Food and Drug Administration‐licensed drugs for IBS‐C comparing their efficacy for abdominal bloating as a specific endpoint.MethodsWe searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) in IBS‐C, with abdominal bloating reported as a dichotomous assessment. Efficacy of each drug was reported as a pooled relative risk (RR) with 95% confidence intervals (CIs) to summarise effect of each comparison tested. Treatments were ranked according to their P‐score.ResultsWe identified 13 eligible RCTs, containing 10 091 patients. Linaclotide 290 µg o.d., lubiprostone 8 µg b.d., tenapanor 50 mg b.d. and tegaserod 6 mg b.d. were all superior to placebo for abdominal bloating in patients with IBS‐C, in both pairwise and the network meta‐analyses. Linaclotide demonstrated the greatest improvement in abdominal bloating in both pairwise and network meta‐analysis (RR of failure to achieve an improvement in abdominal bloating = 0.78; 95% CI 0.74‐0.83, number needed to treat = 7, P‐score 0.97). Indirect comparison revealed no significant differences between individual drugs.ConclusionsWe found all licensed drugs for IBS‐C to be superior to placebo for abdominal bloating. Linaclotide appeared to be the most efficacious at relieving abdominal bloating. Further research is needed to assess long‐term efficacy of these agents and to better understand the precise mechanism of improving bloating.
Visibility of Women at the American College of Gastroenterology Annual Meetings Increasing Over Time
Jansson‐Knodell, Claire , Gayam, Swapna , Kothari, Shivangi , Oxentenko, Amy S. , Bhavsar‐Burke, Indira

Mayo Clinic

American Journal of Gastroenterology | June 11, 2021 | Volume: 116 | Issue: 10 | Pages: 2149-2151

10.14309/ajg.0000000000001345 | PMID 34114569 Get It

Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy
Ryder, Mabel , Wentworth, Mark , Garrity, James, Sanders, Jane, Young, Stuart, Furmaniak, Jadwiga , Smith, Bernard Rees , Ryder, Mabel , Algeciras‐Schimnich, Alicia , Morris, John C., Sanders, Paul W.

Mayo Clinic

Thyroid | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/thy.2021.0053 | PMID 34114495 Get It

Using deep learning to identify bladder cancers with FGFR‐activating mutations from histology images
Velmahos, Constantine S. , Badgeley, Marcus A. , Lo, Ying‐Chun , Badgeley, Marcus, Lo, Ying-Chun

Mayo Clinic

Cancer Medicine | June 11, 2021 | Volume: 10 | Issue: 14 | Pages: 4805-4813

10.1002/cam4.4044 | PMID 34114376 Get It

AbstractBackgroundIn recent years, the fibroblast growth factor receptor (FGFR) pathway has been proven to be an important therapeutic target in bladder cancer. FGFR‐targeted therapies are effective for patients with FGFR mutation, which can be discovered through genetic sequencing. However, genetic sequencing is not commonly performed at diagnosis, whereas a histologic assessment of the tumor is. We aim to computationally extract imaging biomarkers from existing tumor diagnostic slides in order to predict FGFR alterations in bladder cancer.MethodsThis study analyzed genomic profiles and H&E‐stained tumor diagnostic slides of bladder cancer cases from The Cancer Genome Atlas (n = 418 cases). A convolutional neural network (CNN) identified tumor‐infiltrating lymphocytes (TIL). The percentage of the tissue containing TIL (“TIL percentage”) was then used to predict FGFR activation status with a logistic regression model.ResultsThis predictive model could proficiently identify patients with any type of FGFR gene aberration using the CNN‐based TIL percentage (sensitivity = 0.89, specificity = 0.42, AUROC = 0.76). A similar model which focused on predicting patients with only FGFR2/FGFR3 mutation was also found to be highly sensitive, but also specific (sensitivity = 0.82, specificity = 0.85, AUROC = 0.86).ConclusionTIL percentage is a computationally derived image biomarker from routine tumor histology that can predict whether a tumor has FGFR mutations. CNNs and other digital pathology methods may complement genome sequencing and provide earlier screening options for candidates of targeted therapies.
Senescent cells in human adipose tissue: A cross‐sectional study
Ycaza, Ana E. Espinosa De, Søndergaard, Esben , Morgan‐Bathke, Maria , Leon, Barbara Gisella Carranza, Lytle, Kelli A. , Ramos, Paola , Kirkland, James L. , Jensen, Michael D. , Espinosa De Ycaza, Ana Elena, Carranza Leon, Barbara Gisella, Jensen, Michael , Tchkonia, Tamar

Mayo Clinic

Obesity | June 11, 2021 | Volume: 29 | Issue: 8 | Pages: 1320-1327

10.1002/oby.23202 | PMID 34114359 Get It

AbstractObjectiveAdipose tissue (AT) senescence is associated with AT dysfunction in rodents, but little is known about human AT senescence. The study goal was to define the distribution of senescent cells in two subcutaneous depots and understand relationships with adiposity and inflammation.MethodsSixty‐three volunteers (48 females) underwent abdominal and femoral subcutaneous fat biopsies. Fat cell size, senescent cells using senescence‐associated β‐galactosidase staining per 100 nucleated cells (percentage), and mRNA expression of four cytokines were measured.ResultsThere was a larger proportion of senescent cells in femoral than abdominal subcutaneous AT (mean difference 1.6% [95% CI: 0.98%‐2.3%], p < 0.001), and the percentage of femoral AT senescent cells was greater in women than men (median 3.9% vs. 2.1%, p < 0.01). There was a positive correlation between senescence and fat cell size in abdominal (rs = 0.44, p < 0.001) and femoral (rs = 0.35, p = 0.007) AT depots. Abdominal AT tumor necrosis factor alpha (rs = 0.49, p < 0.01) and interleukin‐1β (rs = 0.44, p = 0.01) expression was positively correlated with abdominal, but not femoral, AT senescence.ConclusionsIn human subcutaneous AT, there are more senescent cells in femoral than abdominal depots; abdominal AT senescent cells are more associated with inflammatory signals than femoral AT senescent cells.
Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States
Luu, Michael , Noureddin, Mazen , Nissen, Nicholas N. , Patel, Tushar , Roberts, Lewis R. , Yang, Ju Dong , Patel, Tushar , Yang, Ju Dong , Roberts, Lewis R , Lee, Yi‐Te , Wang, Jasmine Jiemei , Singal, Amit G. , Gores, Gregory J.

Mayo Clinic

Hepatology | June 11, 2021 | Volume: 74 | Issue: 5 | Pages: 2622-2632

10.1002/hep.32007 | PMID 34114675 Get It

Background and Aims Intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) are the most common primary liver cancers (PLCs). Differences in their clinical features and outcomes are open for investigation in a large‐scale study. We aim to investigate the differences in clinical features and outcomes between iCCA and HCC. Approach and Results The Surveillance, Epidemiology, and End Results Program 18 Database (2000‐2017) was used to extract demographic and clinical features of HCC and iCCA patients. Logistic regression analysis was performed to identify factors associated with iCCA diagnosis versus HCC. Cox regression analysis was used to assess factors affecting overall survival (OS). There were 13,611 iCCA and 96,151 HCC patients. Half of iCCA (50.7%) and three quarters of HCC (76.3%) patients were male. Diagnosis in recent year, age (<50 or ≥65), female sex, non‐Hispanic White race, higher income, rural area, and higher tumor burden were independently associated with iCCA diagnosis versus HCC. Patients with iCCA had worse OS than those with HCC (9 vs. 13 months; P < 0.001). However, OS was comparable between iCCA and HCC in multivariable analysis (adjusted hazard ratio [aHR] = 1.02; 95% CI = 0.99‐1.05). In subgroup analyses, iCCA was associated with better OS than HCC in patients with tumor ≥5 cm (aHR = 0.83; 95% CI = 0.80‐0.86), lymph node involvement (aHR = 0.76; 95% CI = 0.72‐0.81), distant metastasis (aHR = 0.76; 95% CI = 0.73‐0.79), poorly/undifferentiated tumors (aHR = 0.88; 95% CI = 0.83‐0.94), and those receiving noncurative treatment (aHR = 0.96; 95% CI = 0.93‐0.98). Conclusions We identified the demographic, socioeconomic, and clinical features associated with iCCA diagnosis over HCC among patients with PLC. Although iCCA patients presented at an advanced stage, OS was similar between iCCA and HCC in multivariable analysis. iCCA was associated with longer OS for subgroups with poor prognostic features.
Long‐term cognitive and academic outcomes among pediatric brain tumor survivors treated with proton versus photon radiotherapy
Child, Amanda , Warren, Emily , Grosshans, David R. , Paulino, Arnold C. , Okcu, M. Fatih , Ris, M. Douglas , Mahajan, Anita , Orobio, Jéssica , Cirino, Paul T. , Viana, Andres G. , Bick, Johanna , Chintagumpala, Murali , Kahalley, Lisa S. , Child, Amanda E , Paulino, Arnold C , Kahalley, Lisa S , Minard, Charles G. , Woods, Steven Paul

Mayo Clinic

Pediatric Blood & Cancer | June 11, 2021 | Volume: 68 | Issue: 9 | Pages: No page available

10.1002/pbc.29125 | PMID 34114294 Get It

Abstract Background Proton radiotherapy (PRT) may be associated with less neurocognitive risk than photon RT (XRT) for pediatric brain tumor survivors. We compared neurocognitive and academic outcomes in long‐term survivors treated with XRT versus PRT. Methods Survivors underwent neurocognitive evaluation >1 year after craniospinal (CSI) or focal PRT or XRT. Groups were compared using separate one‐way analyses of covariance for the CSI and focal groups. Results PRT ( n = 58) and XRT ( n = 30) subgroups were similar on gender (66% male), age at RT (median = 6.5 years), age at follow‐up (median = 14.6 years), and government assistance status (32%). PRT and XRT focal groups differed on follow‐up interval, shunt history, and total RT dose (all p < .05), whereas PRT and XRT CSI groups differed on follow‐up interval, baseline neurocognitive performance score, boost volume, and CSI dose (all p < .05). The PRT focal group outperformed the XRT focal group on inhibition/switching ( p = .04). The PRT CSI group outperformed the XRT CSI group on inattention/impulsivity (both p < .05). Several clinical variables (i.e., RT dose, boost field, baseline performance) predicted neurocognitive outcomes (all p < .05). The PRT focal group performed comparably to population means on most neurocognitive measures, while both CSI groups performed below expectation on multiple measures. The XRT CSI group was most impaired. All groups fell below expectation on processing speed, fine motor, and academic fluency (most p < .01). Conclusions Findings suggest generally favorable neurocognitive and academic long‐term outcomes following focal PRT. Impairment was greatest following CSI regardless of modality. Dosimetry and baseline characteristics are important determinants of outcome alone or in combination with modality.
Influence of supramarginal resection on survival outcomes after gross-total resection of IDH–wild-type glioblastoma
Vivas-Buitrago, Tito, Domingo, Ricardo A., Tripathi, Shashwat, Biase, Gaetano De, Brown, Desmond, Akinduro, Oluwaseun O., Ramos-Fresnedo, Andres, Sabsevitz, David S., Bendok, Bernard R., Sherman, Wendy, Parney, Ian F., Jentoft, Mark E., Middlebrooks, Erik H., Meyer, Fredric B., Chaichana, Kaisorn L., Quinones-Hinojosa, Alfredo, Middlebrooks, Erik H. , Tripathi, Shashwat , Biase, Gaetano De , Sherman, Wendy , Middlebrooks, Erik H , De Biase, Gaetano , Sherman, Wendy Joyce , Vivas-Buitrago, Tito, Domingo, Ricardo A., Tripathi, Shashwat, Brown, Desmond, Akinduro, Oluwaseun O., Ramos-Fresnedo, Andres, Sabsevitz, David S., Bendok, Bernard R., Parney, Ian F., Jentoft, Mark E., Meyer, Fredric B., Chaichana, Kaisorn L., Quinones-Hinojosa, Alfredo

Mayo Clinic

Journal of Neurosurgery | June 11, 2021 | Volume: 136 | Issue: 1 | Pages: 1-8

10.3171/2020.10.jns203366 | PMID 34087795 Get It

OBJECTIVE The authors’ goal was to use a multicenter, observational cohort study to determine whether supramarginal resection (SMR) of FLAIR-hyperintense tumor beyond the contrast-enhanced (CE) area influences the overall survival (OS) of patients with isocitrate dehydrogenase–wild-type (IDH-wt) glioblastoma after gross-total resection (GTR). METHODS The medical records of 888 patients aged ≥ 18 years who underwent resection of GBM between January 2011 and December 2017 were reviewed. Volumetric measurements of the CE tumor and surrounding FLAIR-hyperintense tumor were performed, clinical variables were obtained, and associations with OS were analyzed. RESULTS In total, 101 patients with newly diagnosed IDH-wt GBM who underwent GTR of the CE tumor met the inclusion criteria. In multivariate analysis, age ≥ 65 years (HR 1.97; 95% CI 1.01–2.56; p < 0.001) and contact with the lateral ventricles (HR 1.59; 95% CI 1.13–1.78; p = 0.025) were associated with shorter OS, but preoperative Karnofsky Performance Status ≥ 70 (HR 0.47; 95% CI 0.27–0.89; p = 0.006), MGMT promotor methylation (HR 0.63; 95% CI 0.52–0.99; p = 0.044), and increased percentage of SMR (HR 0.99; 95% CI 0.98–0.99; p = 0.02) were associated with longer OS. Finally, 20% SMR was the minimum percentage associated with beneficial OS (HR 0.56; 95% CI 0.35–0.89; p = 0.01), but > 60% SMR had no significant influence (HR 0.74; 95% CI 0.45–1.21; p = 0.234). CONCLUSIONS SMR is associated with improved OS in patients with IDH-wt GBM who undergo GTR of CE tumor. At least 20% SMR of the CE tumor was associated with beneficial OS, but greater than 60% SMR had no significant influence on OS.